Allegheny Endocrinology Associates

Pittsburgh, Pennsylvania 15212

0 studies enrolling now · 17 studies all time

What they study most

Acromegaly, Adult Growth Hormone Deficiency, Cardiovascular Disease, Cushing's Disease, Cushings Disease, Diabetes Mellitus, Gastroparesis, Hyperlipidemia, Hypothalamic-pituitary Disorders, Obesity, Overweight

Studies at this site

• A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly — Completed
• An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) — Completed
• Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease — Completed
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly — Completed
• A Study of LY3437943 in Participants Who Have Obesity or Are Overweight — Completed
• Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 — Stopped early
• Diabetic Gastroparesis Study 05 — Stopped early
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 — Stopped early
• Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02 — Stopped early
• Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly — Status unconfirmed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. — Completed
• Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly — Completed
• The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis — Completed